EU once again rejects Vivus weight drug; Abbott inks deal to develop new test for ibrutinib;

 @FierceBiotech: FDA approved T-DM1 for patients with HER2-positive breast cancer. Story | Follow @FierceBiotech

@JohnCFierce: Elan lines up biotech deals as it preps for $3B Tysabri windfall. Report | Follow @JohnCFierce

> European regulators have once again turned their thumbs down on Vivus' ($VVUS) new weight drug. And they say that there will be no approval unless Vivus bites the bullet and does a big heart study first. Story

> Abbott ($ABT) has struck a deal with J&J ($JNJ) and Pharmacyclics ($PCYC) to develop a new molecular test to be used to identify patients most likely to benefit from the experimental cancer drug ibrutinib. Report

> The commercialization arm of The Centre for Drug Research and Development and Pfizer ($PFE) today announced a strategic collaboration designed to offer new resources to advance Canada's most innovative and therapeutically promising health technologies towards commercialization. Release

> A new study concludes that after 2006 the number of new drugs being introduced in the U.K. has been rising--not dwindling as many had feared. Story

Pharma News

@FiercePharma: Sanofi's new 6-in-1 vaccine won backing from Europe's CHMP. Would compete with $GSK's Infanrix Hexa. News | Follow @FiercePharma

@EricPFierce: Elan CEO Martin gives shareholders a taste of honey. More | Follow @EricPFierce

@AlisonBFierce: The flu vaccine was effective in only 56% of those who received it, largely failing to protect against the elderly. More | Follow @AlisonBFierce

> Board, Vasella slammed for handling of retirement prize. Article

> Elan shareholders to get taste of $3.25B windfall. News

> Warburg persists in trying to unload Bausch + Lomb. Story

Medical Device News

 @FierceMedDev: Abbott chops 200 jobs at Ireland plant. Story | Follow @FierceMedDev

 @MarkHFierce: A cancer diagnostic test you could use yourself in the bathroom at home? It's coming... More | Follow @MarkHFierce

 @DamianFierce: Despite a revenue jump, Volcano's profits tanked in Q4. News | Follow @DamianFierce

> J&J's DePuy recalls knee component over risk of limb loss. Story

> Stryker sued over metal-hip safety shortfalls. Item

> Abiomed gets out from under FDA's Impella warning letter. Report

And Finally… Investigators at CSIRO, the University of British Columbia and the University of Bath say they have designed a new treatment to guard against epidemic and pandemic flu strains. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.